Literature DB >> 11861616

CpG motifs in bacterial DNA and their immune effects.

Arthur M Krieg1.   

Abstract

Unmethylated CpG motifs are prevalent in bacterial but not vertebrate genomic DNAs. Oligodeoxynucleotides (ODN) containing CpG motifs activate host defense mechanisms leading to innate and acquired immune responses. The recognition of CpG motifs requires Toll-like receptor (TLR) 9, which triggers alterations in cellular redox balance and the induction of cell signaling pathways including the mitogen activated protein kinases (MAPKs) and NF kappa B. Cells that express TLR-9, which include plasmacytoid dendritic cells (PDCs) and B cells, produce Th1-like proinflammatory cytokines, interferons, and chemokines. Certain CpG motifs (CpG-A) are especially potent at activating NK cells and inducing IFN-alpha production by PDCs, while other motifs (CpG-B) are especially potent B cell activators. CpG-induced activation of innate immunity protects against lethal challenge with a wide variety of pathogens, and has therapeutic activity in murine models of cancer and allergy. CpG ODN also enhance the development of acquired immune responses for prophylactic and therapeutic vaccination.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11861616     DOI: 10.1146/annurev.immunol.20.100301.064842

Source DB:  PubMed          Journal:  Annu Rev Immunol        ISSN: 0732-0582            Impact factor:   28.527


  634 in total

1.  'Immunomers'--novel 3'-3'-linked CpG oligodeoxyribonucleotides as potent immunomodulatory agents.

Authors:  Dong Yu; Ekambar R Kandimalla; Lakshmi Bhagat; Jin-Yan Tang; Yanping Cong; Jimmy Tang; Sudhir Agrawal
Journal:  Nucleic Acids Res       Date:  2002-10-15       Impact factor: 16.971

Review 2.  DNA-Based Biomaterials for Immunoengineering.

Authors:  Midori Maeda; Taisuke Kojima; Yang Song; Shuichi Takayama
Journal:  Adv Healthc Mater       Date:  2018-12-05       Impact factor: 9.933

3.  Treatment with cationic liposome-DNA complexes (CLDCs) protects mice from lethal Western equine encephalitis virus (WEEV) challenge.

Authors:  Christopher H Logue; Aaron T Phillips; Eric C Mossel; Jeremy P Ledermann; Thomas Welte; Steve W Dow; Ken E Olson; Ann M Powers
Journal:  Antiviral Res       Date:  2010-05-07       Impact factor: 5.970

Review 4.  Plasticity in programming of effector and memory CD8 T-cell formation.

Authors:  Ramon Arens; Stephen P Schoenberger
Journal:  Immunol Rev       Date:  2010-05       Impact factor: 12.988

5.  Molecular characterization of in vivo adjuvant activity in ferrets vaccinated against influenza virus.

Authors:  Yuan Fang; Thomas Rowe; Alberto J Leon; David Banner; Ali Danesh; Luoling Xu; Longsi Ran; Steven E Bosinger; Yi Guan; Honglin Chen; Cheryl C Cameron; Mark J Cameron; David J Kelvin
Journal:  J Virol       Date:  2010-06-09       Impact factor: 5.103

6.  The Toll-like receptor 9 signalling pathway regulates MR1-mediated bacterial antigen presentation in B cells.

Authors:  Jianyun Liu; Randy R Brutkiewicz
Journal:  Immunology       Date:  2017-06-29       Impact factor: 7.397

7.  Toll-like receptor 9 and 21 have different ligand recognition profiles and cooperatively mediate activity of CpG-oligodeoxynucleotides in zebrafish.

Authors:  Da-Wei Yeh; Yi-Ling Liu; Yin-Chiu Lo; Chiou-Hwa Yuh; Guann-Yi Yu; Jeng-Fan Lo; Yunping Luo; Rong Xiang; Tsung-Hsien Chuang
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-26       Impact factor: 11.205

Review 8.  Harnessing cancer immunotherapy during the unexploited immediate perioperative period.

Authors:  Pini Matzner; Elad Sandbank; Elad Neeman; Oded Zmora; Vijaya Gottumukkala; Shamgar Ben-Eliyahu
Journal:  Nat Rev Clin Oncol       Date:  2020-02-17       Impact factor: 66.675

9.  Effect of CpG oligodeoxynucleotides on the immunogenicity of Pfs25, a Plasmodium falciparum transmission-blocking vaccine antigen.

Authors:  Cevayir Coban; Ken J Ishii; Anthony W Stowers; David B Keister; Dennis M Klinman; Nirbhay Kumar
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

10.  Preinfection treatment of resistant mice with CpG oligodeoxynucleotides renders them susceptible to friend retrovirus-induced leukemia.

Authors:  Anke R M Olbrich; Simone Schimmer; Ulf Dittmer
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.